Deutsch English Français

Contact

EP2852689

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2852689

EP2852689 - NANO46 GENES AND METHODS TO PREDICT BREAST CANCER OUTCOME [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 16.10.2020 Database last updated on 20.05.2024
Former	The patent has been granted Status updated on 08.11.2019
Former	Grant of patent is intended Status updated on 02.07.2019
Former	Examination is in progress Status updated on 21.04.2017
Most recent event Tooltip	08.07.2022	Lapse of the patent in a contracting state New state(s): MK	published on 10.08.2022 [2022/32]
Applicant(s)	For all designated states Nanostring Technologies, Inc. 530 Fairview Avenue North, Suite 2000 Seattle, WA 98109 / US
	For all designated states The University of North Carolina at Chapel Hill 100 Europa Drive, Suite 430 Chapel Hill, NC 27517 / US
	For all designated states University of Utah Research Foundation 615 Arapeen Drive, Suite 310 Salt Lake City, UT 84108 / US
	For all designated states Washington University One Brookings Drive Saint Louis, MO 63130 / US
	For all designated states British Columbia Cancer Agency Branch 675 West 10th Avenue Vancouver, British Columbia V5Z 1L3 / CA
	[2019/50]
Former [2015/14]	For all designated states Nanostring Technologies, Inc. 530 Fairview Avenue North, Suite 2000 Seattle, WA 98109 / US
	For all designated states The University of North Carolina at Chapel Hill 100 Europa Drive, Suite 430 Chapel Hill, NC 27517 / US
	For all designated states University of Utah Research Foundation 615 Arapeen Drive, Suite 310 Salt Lake City, UT 84108 / US
	For all designated states Washington University One Brookings Drive Saint Louis, MO 63130 / US
	For all designated states British Columbia Cancer Agency Branch 675 West 10th Avenue Vancouver, British Columbia V5Z 1L3 / CA
Inventor(s)	01 / FERREE, Sean M. 7018 3rd Avenue NW Seattle, WA 98117 / US
	02 / STORHOFF, James Justin 6520 36th Avenue NW Seattle, WA 98117 / US
	03 / PARKER, Joel S. 1113 Churchwood Drive Apex, NC 27502 / US
	04 / PEROU, Charles M. 103 Oak Spring Court Carrboro, NC 27510 / US
	05 / ELLIS, Matthew J. 226 Spencer Road St. Louis, MO 63119 / US
	06 / BERNARD, Philip S. 1375 East Bryan Avenue Salt Lake City, UT 84105 / US
	07 / NIELSEN, Torsten O. 4360 Canterbury Crescent North Vancouver, BC V7R 3N6 / CA
	[2015/14]
Representative(s)	Cooley (UK) LLP 22 Bishopsgate London EC2N 4BQ / GB
	[N/P]
Former [2019/50]	Cooley (UK) LLP Dashwood 69 Old Broad Street London EC2M 1QS / GB
Former [2015/14]	Jappy, John William Graham Gill Jennings & Every LLP The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
Application number, filing date	13794236.3	22.05.2013
	[2019/50]
	WO2013US42157
Priority number, date	US201261650209P	22.05.2012 Original published format: US 201261650209 P
	US201361753673P	17.01.2013 Original published format: US 201361753673 P
	[2015/14]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2013177245
	Date:	28.11.2013
	Language:	EN
	[2013/48]
	Type:	A2 Application without search report
	No.:	EP2852689
	Date:	01.04.2015
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 28.11.2013 takes the place of the publication of the European patent application.
	[2015/14]
	Type:	B1 Patent specification
	No.:	EP2852689
	Date:	11.12.2019
	Language:	EN
	[2019/50]
Search report(s)	International search report - published on:	US	29.01.2015
	(Supplementary) European search report - dispatched on:	EP	12.04.2016
Classification	IPC:	C12Q1/68	[2015/14]
	CPC:	C12Q1/6886 (EP,CN,US); C12Q2600/118 (EP,CN,US); C12Q2600/158 (EP,CN,US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/14]
Extension states	BA	26.11.2014
	ME	26.11.2014
Title	German:	NANO46-GENE UND VERFAHREN ZUR VORHERSAGE VON BRUSTKREBSERGEBNISSEN	[2015/14]
	English:	NANO46 GENES AND METHODS TO PREDICT BREAST CANCER OUTCOME	[2015/14]
	French:	GÈNES NANO-46 ET PROCÉDÉS DE PRÉDICTION DE L'ÉVOLUTION DU CANCER DU SEIN	[2015/14]
Entry into regional phase	26.11.2014	National basic fee paid
	26.11.2014	Search fee paid
	26.11.2014	Designation fee(s) paid
	26.11.2014	Examination fee paid
Examination procedure	26.11.2014	Examination requested [2015/14]
	14.11.2016	Amendment by applicant (claims and/or description)
	21.04.2017	Despatch of a communication from the examining division (Time limit: M06)
	11.10.2017	Reply to a communication from the examining division
	16.02.2018	Despatch of a communication from the examining division (Time limit: M06)
	17.08.2018	Reply to a communication from the examining division
	20.02.2019	Despatch of a communication from the examining division (Time limit: M02)
	02.05.2019	Reply to a communication from the examining division
	03.07.2019	Communication of intention to grant the patent
	04.11.2019	Fee for grant paid
	04.11.2019	Fee for publishing/printing paid
	04.11.2019	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 21.04.2017
Opposition(s)	14.09.2020	No opposition filed within time limit [2020/47]
Fees paid	Renewal fee
	27.05.2015	Renewal fee patent year 03
	27.05.2016	Renewal fee patent year 04
	30.05.2017	Renewal fee patent year 05
	29.05.2018	Renewal fee patent year 06
	28.05.2019	Renewal fee patent year 07
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	22.05.2013
	AL	11.12.2019
	AT	11.12.2019
	CY	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	MK	11.12.2019
	MT	11.12.2019
	NL	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	TR	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
	LU	22.05.2020
	BE	31.05.2020
	[2022/32]
Former [2022/27]	HU	22.05.2013
	AL	11.12.2019
	AT	11.12.2019
	CY	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	MT	11.12.2019
	NL	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	TR	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
	LU	22.05.2020
	BE	31.05.2020
Former [2022/26]	AL	11.12.2019
	AT	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	NL	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	TR	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
	LU	22.05.2020
	BE	31.05.2020
Former [2021/24]	AL	11.12.2019
	AT	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	NL	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
	LU	22.05.2020
	BE	31.05.2020
Former [2021/15]	AL	11.12.2019
	AT	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	NL	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
	LU	22.05.2020
Former [2021/12]	AL	11.12.2019
	AT	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	MC	11.12.2019
	NL	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/51]	AL	11.12.2019
	AT	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	PL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SI	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/47]	AL	11.12.2019
	CZ	11.12.2019
	DK	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/40]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	IS	11.04.2020
	PT	06.05.2020
Former [2020/37]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	SK	11.12.2019
	SM	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	PT	06.05.2020
Former [2020/36]	AL	11.12.2019
	CZ	11.12.2019
	EE	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
	PT	06.05.2020
Former [2020/35]	AL	11.12.2019
	CZ	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	RO	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/32]	AL	11.12.2019
	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	NL	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/26]	FI	11.12.2019
	HR	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	RS	11.12.2019
	SE	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/23]	FI	11.12.2019
	LT	11.12.2019
	LV	11.12.2019
	SE	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
	GR	12.03.2020
Former [2020/22]	FI	11.12.2019
	LT	11.12.2019
	SE	11.12.2019
	BG	11.03.2020
	NO	11.03.2020
Former [2020/21]	NO	11.03.2020
Documents cited:	Search	[I]EP1641810 (GENOMIC HEALTH [US]) [I] 1-15 * the whole document *;
		[X]WO2008150512 (UNIV LOUISVILLE RES FOUND [US], et al) [X] 1-15 * the whole document *;
		[I]WO2009108215 (AVIARADX INC [US], et al) [I] 1-15 * the whole document *;
		[X]WO2009158143 (UNIV NORTH CAROLINA [US], et al) [X] 1-15 * the whole document *;
		[I]WO2011120984 (SIVIDON DIAGNOSTICS GMBH [DE], et al) [I] 1-15 * the whole document *;
		[X] - PARKER JOEL S ET AL, "Supervised risk predictor of breast cancer based on intrinsic subtypes", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, (20090310), vol. 27, no. 8, doi:10.1200/JCO.2008.18.1370, ISSN 0732-183X, pages 1160 - 1167, XP009124878 [X] 1-15 * the whole document * DOI: http://dx.doi.org/10.1200/JCO.2008.18.1370
		[I] - MULLINS M ET AL, "Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, vol. 53, no. 7, doi:10.1373/CLINCHEM.2006.083725, ISSN 0009-9147, (20070701), pages 1273 - 1279, (20070524), XP002553359 [I] 1-15 * the whole document * DOI: http://dx.doi.org/10.1373/clinchem.2006.083725
		[I] - PLUCIENNIK ELZBIETA ET AL, "Breast cancer relapse prediction based on multi-gene RT-PCR algorithm.", MEDICAL SCIENCE MONITOR : INTERNATIONAL MEDICAL JOURNAL OF EXPERIMENTAL AND CLINICAL RESEARCH MAR 2010, (201003), vol. 16, no. 3, ISSN 1643-3750, pages CR132 - CR136, XP002755989 [I] 1-15 * the whole document *
		[I] - SORLIE T ET AL, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, (20010911), vol. 98, no. 19, doi:10.1073/PNAS.191367098, ISSN 0027-8424, pages 10869 - 10874, XP002215483 [I] 1-15 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.191367098
		[X] - "AFFYMETRIX GENECHIP HUMAN GENOME U133 ARRAY SET HG-U133A", GEO, (20020311), XP002506341 [X] 8-11 * the whole document *
	International search	[Y]US2010015607 (GEISS GARY K [US], et al);
		[X]US2011145176 (PEROU CHARLES M [US], et al);
		[A] - VAN DE VIJVER, MJ ET AL., "A Gene - Expression Signature As A Predictor Of Survival In Breast Cancer.", THE NEW ENGLAND JOUMAL OF MEDICINE., (20021219), vol. 347, no. 25, pages 1999 - 2009, XP008032093 DOI: http://dx.doi.org/10.1056/NEJMoa021967
	by applicant	US5384261
		US5708153
		US5770358
		US5789162
		US5800992
		US5856174
		US5922591
		US6020135
		US6033860
		US6040138
		US6040193
		US6344316
		EP1641810
		WO2007061876
		WO2007076129
		WO2007076132
		US2008032293
		WO2008124847
		US2009299640
		WO2009158143
		US2010015607
		WO2010019826
		US2010047924
		US2010261026
		US8415102
		- PARKER JOEL S et al., "Supervised risk predictor of breast cancer based on intrinsic subtypes", J. of Clinincal Oncology, Americal Soc. of Clinical Oncology, (20190310), vol. 27, no. 8, doi:doi:10.1200/JCO.2008.18.1370, pages 1160 - 1167, XP009124878 DOI: http://dx.doi.org/10.1200/JCO.2008.18.1370
		- PEROU et al., Nature, (20000000), vol. 406, no. 6797, pages 747 - 52
		- SORLIE et al., PNAS, (20010000), vol. 98, no. 19, pages 10869 - 74
		- NIELSEN et al., Clin. Cancer Res., (20090000), vol. 16, no. 21, pages 5222 - 5232
		- JAY R. HARRIS et al., Diseases of the breast, Lippincott Williams & Wilkins, pages 458 - 472
		- NARASHIMAN; CHU, PNAS, (20020000), vol. 99, pages 6567 - 6572
		- WEIS et al., TIG, (19920000), vol. 8, pages 263 - 64
		- SCHENA et al., Science, (19950000), vol. 270, pages 467 - 70
		- GEISS et al., Nature Biotechnology, (20080000), vol. 26, no. 3, pages 317 - 325
		- QUACKENBUSH, Nat. Genet., (20020000), vol. 32, pages 496 - 501
		- BENITO et al., Bioinformatics, (20040000), vol. 20, no. 1, pages 105 - 114
		- ROUZIER et al., J Clin Oncol, (20050000), vol. 23, pages 8331 - 9
		- SPRUANCE et al., Antimicrob. Agents & Chemo, (20040000), vol. 48, pages 2787 - 92

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p